DDIT3 and leiomyosarcoma: For example, trabectedin is clinically effective against leiomyosarcomas and liposarcomas where it interferes with the ability of FUS-CHOP to bind its target promoters.221–223 Trabectedin was FDA-approved for these sarcoma subtypes in 2015 and is currently in clinical trials for other sarcoma subtypes (NCT02367924, NCT02275286, NCT04076579, NCT01303094, NCT04067115).